In the trial, 76 percent of genotype 1 HCV treatment-naive patients receiving 24 weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin achieved a sustained virologic response 12 weeks after completing therapy .
http://www.businesswire.com/news/home/20131102005010/en/Gilead-Announces-Phase-3-Results-All-Oral-Sofosbuvir-Based
http://www.businesswire.com/news/home/20131102005010/en/Gilead-Announces-Phase-3-Results-All-Oral-Sofosbuvir-Based
No comments:
Post a Comment